Jazz Pharmaceuticals plc EPS (Earnings per Share) 2009–2025
Jazz Pharmaceuticals plc reported $-5.84 of earnings per share for fiscal 2025. That was 167.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -238.4%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $-5.84 | -167.5% |
| FY 2024 | $8.65 | +41.8% |
| FY 2023 | $6.10 | +270.4% |
| FY 2022 | $-3.58 | +35.1% |
| FY 2021 | $-5.52 | -230.8% |
| FY 2020 | $4.22 | -53.6% |
| FY 2019 | $9.09 | +24.5% |
| FY 2018 | $7.30 | -8.3% |
| FY 2017 | $7.96 | +24.2% |
| FY 2016 | $6.41 | +22.6% |
| FY 2015 | $5.23 | +462.4% |
| FY 2014 | $0.93 | -73.5% |
| FY 2013 | $3.51 | -26.7% |
| FY 2012 | $4.79 | +79.4% |
| FY 2011 | $2.67 | +221.7% |
| FY 2010 | $0.83 | +460.9% |
| FY 2009 | $-0.23 | — |
Source: Jazz Pharmaceuticals plc SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open JAZZ 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Jazz Pharmaceuticals plc reported $-5.84 of earnings per share for fiscal 2025. That was 167.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -238.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Jazz Pharmaceuticals plc
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeJazz Pharmaceuticals plc — frequently asked questions
What is Jazz Pharmaceuticals plc's earnings per share?
Jazz Pharmaceuticals plc (JAZZ) reported earnings per share of $-5.84 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Jazz Pharmaceuticals plc's official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.